Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2,166 JPY | +1.52% | -0.14% | -12.15% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- The stock, which is currently worth 2025 to 0.38 times its sales, is clearly overvalued in comparison with peers.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analyst opinion has improved significantly over the past four months.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company is not the most generous with respect to shareholders' compensation.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-12.15% | 2.85B | C- | ||
-37.88% | 13.99B | B- | ||
-33.12% | 10.67B | B | ||
+12.54% | 6.29B | C | ||
-11.17% | 5.88B | C+ | ||
+75.00% | 4.96B | C | ||
-4.38% | 4.54B | D- | ||
-9.20% | 3.74B | B | ||
-19.40% | 3.16B | C- | ||
-12.99% | 2.53B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 3141 Stock
- Ratings Welcia Holdings Co., Ltd.